India Pharma Outlook Team | Tuesday, 17 November 2026
Rare disease drug advances take center stage as AstraZeneca secures two important US approvals that expand treatment choices for patients.
The company gains an expanded bladder cancer use for its immunotherapy Imfinzi and a first-of-its-kind therapy for a rare muscle-weakening disorder.
These decisions deliver more practical options in oncology and rare disease care.
Patients who previously faced limited choices now gain clearer paths forward. The dual nod highlights AstraZeneca’s progress in addressing serious conditions with meaningful clinical benefits.
AstraZeneca receives FDA approval for Imfinzi combined with enfortumab vedotin as treatment prior to surgery for muscle-invasive bladder cancer patients who remain ineligible for or refuse cisplatin-based chemotherapy.
The late-stage trial shows the regimen cuts the risk of cancer recurrence by 49 percent and the risk of death by 42 percent. Imfinzi already holds approval across more than 50 countries and treats a range of cancers including lung and bladder.
Also Read: 5 Women Leaders Driving India's Pharma and Healthcare Innovation
AstraZeneca’s rare disease unit Alexion develops Klygefa, which the FDA approves for adults with generalized myasthenia gravis who carry antibodies that attack proteins on the nerves and disrupt communication with muscles.
Klygefa also wins approval in the EU on the same day and adds to earlier clearances in Japan and other countries. The therapy eases daily treatment burden by giving patients a practical new option.
These two approvals strengthen AstraZeneca’s position in both oncology and rare disease while offering clearer treatment paths for patients who previously had limited choices.